NextCure, Inc.
- Open
- 6.29
- Day high
- 6.56
- Day low
- 6.11
- Prev close
- 6.09
- Volume
- 54K
- Mkt cap
- $29M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.4
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $1.3M over the last 3 months (11 open-market buys, 1 sale)
- 🏛Institutions reducing (13F)
NextCure, Inc. (NXTC) is a Healthcare company listed on NASDAQ. The stock is up 26% over the past year. Over the trailing 3 months, insiders filed 11 open-market buys and 1 sale (SEC Form 4).
NextCure, Inc. (NXTC) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NXTC earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-1.95 | $-2.80 | -43.6% | — | — |
| May 7, 2026 | $-1.81 | $-1.87 | -3.3% | — | — |
| Mar 5, 2026 | $-2.26 | $-0.81 | +64.2% | — | — |
| Nov 5, 2025 | $-4.06 | $-3.22 | +20.7% | — | — |
| Aug 7, 2025 | $-4.62 | $-11.29 | -144.4% | — | — |
| May 1, 2025 | $-4.80 | $-4.68 | +2.5% | — | — |
| Mar 6, 2025 | $-0.34 | $-0.41 | -20.6% | — | — |
| Nov 7, 2024 | $-0.35 | $-0.41 | -17.1% | — | — |
| Aug 1, 2024 | $-0.36 | $-0.55 | -52.8% | — | — |
| May 2, 2024 | $-0.45 | $-0.61 | -35.6% | — | — |
| Mar 21, 2024 | $-0.54 | $-0.52 | +3.7% | $6M | — |
| Nov 2, 2023 | $-0.64 | $-0.51 | +20.3% | — | — |
NXTC insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 12, 2026 | Simcere Zaiming, Inc.other: Former 10% Owner | Sell | 30,000 | $6.16 |
| Aug 3, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 100,000 | $4.90 |
| Aug 3, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 77,850 | $4.96 |
| Aug 3, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 3,300 | $4.98 |
| Aug 3, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 8,003 | $4.80 |
| Aug 3, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 25,000 | $4.81 |
| Aug 3, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 50,000 | $4.97 |
| Aug 3, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 20,000 | $5.00 |
| Jul 29, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 1,810 | $5.00 |
| Jul 29, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 1,600 | $5.00 |
| Jul 29, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 7,798 | $5.00 |
| Jul 29, 2026 | ADAR1 Capital Management, LLC10 percent owner | Buy | 6,400 | $4.95 |
| Jun 22, 2026 | Houston John Gdirector | Grant | 2,340 | $2.02 |
| Jun 22, 2026 | KABAKOFF DAVID Sdirector | Grant | 3,510 | $2.02 |
| Jun 22, 2026 | Webster Stephen Wdirector | Grant | 2,340 | $2.02 |
Source: NXTC SEC Form 4 filings, latest Aug 12, 2026. For informational purposes only — not investment advice.
See the full NXTC insider & 13F page →NextCure, Inc. company profile
Overview
NextCure, Inc. (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Beltsville, Maryland. The company went public in May 2019 and focuses on discovering and developing novel immunotherapies to treat cancer and other immune-related diseases. NextCure's approach centers on restoring normal immune function through targeted immunomodulation, representing a specialized segment within the broader cancer immunotherapy field.
Business
NextCure operates in the biotechnology sector, specifically within the cancer immunotherapy space. The company develops immunomedicines - therapeutic antibodies designed to modulate the immune system's response to cancer cells. Unlike traditional chemotherapy that directly attacks cancer cells, immunotherapy works by enhancing or restoring the body's natural immune system to recognize and eliminate cancer cells more effectively. The company's pipeline consists of several product candidates at various stages of development. NC318 serves as the lead product candidate, currently in Phase II clinical trials for treating advanced or metastatic solid tumors. This drug targets specific immune checkpoint pathways that cancer cells exploit to evade immune detection. NC410 is in Phase I trials and represents a novel approach to blocking immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1), which is often overexpressed in various cancers. Additional pipeline assets include NC762, which targets the B7-H4 protein, another immune checkpoint molecule, and NC525, a LAIR-1 antibody in preclinical development specifically designed to target acute myeloid leukemia cells and leukemic stem cells. The company also maintains discovery programs exploring other novel immunomodulatory targets. NextCure operates under a licensing agreement with Yale University, suggesting academic collaboration in its research efforts.
Revenue model
As a clinical-stage biopharmaceutical company, NextCure currently generates no revenue from product sales, as evidenced by zero revenue across all reported periods. The company operates on a research and development model typical of early-stage biotech firms, funded primarily through equity financing, grants, and potential future partnerships or licensing deals. The company's future revenue model will likely depend on successful clinical trials leading to regulatory approval and commercialization of its drug candidates. Potential revenue streams include direct product sales following FDA approval, licensing agreements with larger pharmaceutical companies, milestone payments from development partnerships, and royalties from licensed technologies. The company's substantial cash burn rate of approximately $41-53 million annually reflects the high costs associated with clinical trial operations, research and development activities, and regulatory compliance. Factors that could positively impact future margins include successful clinical trial outcomes leading to premium pricing for novel immunotherapies, potential partnerships with major pharmaceutical companies that could provide upfront payments and shared development costs, and the ability to leverage successful drug platforms across multiple indications. Conversely, margin pressures could arise from clinical trial failures requiring additional studies, increased competition in the immunotherapy space potentially limiting pricing power, rising clinical development costs, and the need for substantial manufacturing and commercialization investments upon regulatory approval.
Competitive moat
NextCure's competitive position relies primarily on its proprietary research platform and intellectual property portfolio rather than traditional economic moats. The company's approach to targeting novel immune checkpoints like LAIR-1 and B7-H4 provides some differentiation in the crowded immunotherapy landscape, as these targets are less extensively pursued compared to established checkpoints like PD-1 and CTLA-4. However, the company's moat appears relatively narrow given the highly competitive nature of cancer immunotherapy development. Major pharmaceutical companies with significantly greater resources are actively developing competing immunotherapies, and the barriers to entry in biotechnology are primarily scientific and regulatory rather than economic. The company's licensing agreement with Yale University and any proprietary discoveries may provide some intellectual property protection, but the strength and breadth of these patents are not clearly established. The primary competitive threats come from larger biopharmaceutical companies with more extensive resources, established clinical development capabilities, and existing market presence. Additionally, the rapid pace of innovation in immunotherapy means that novel approaches could potentially supersede NextCure's current pipeline. The company's small size and limited financial resources compared to industry giants like Bristol Myers Squibb, Merck, and Roche present significant competitive disadvantages in terms of clinical trial execution speed and scale.
Risks & safety
NextCure exhibits a precarious financial position typical of clinical-stage biotechnology companies, with significant cash burn and no revenue generation. • **Cash Position**: $21.8 million in cash and short-term investments as of Q1 2025, down from $27.7 million in Q4 2024 • **Burn Rate**: Approximately $13 million quarterly cash burn from operations, suggesting roughly 1.5-2 quarters of runway at current spending levels • **Debt Level**: Minimal debt with debt-to-equity ratio of 0.088, indicating low financial leverage • **Solvency Risk**: High near-term solvency risk given rapid cash depletion and no revenue • **Valuation Metrics**: Trading at 0.24x book value and negative earnings multiples due to losses • **Current Ratio**: Strong at 10.3x, indicating good short-term liquidity coverage • **Other Considerations**: Company will likely need additional financing within the next 6-12 months to continue operations and fund clinical trials
Recent development
Based on the available financial data, NextCure has been progressing its clinical pipeline while managing significant cash burn. The company's lead asset NC318 has advanced to Phase II trials for solid tumors, representing a key milestone in its development trajectory. The progression of NC410 into Phase I trials demonstrates the company's ability to advance multiple assets simultaneously through its development pipeline. The company has maintained its focus on novel immune checkpoint targets, particularly LAIR-1 and B7-H4, which differentiate it from competitors targeting more established pathways. The development of NC525 specifically for acute myeloid leukemia suggests strategic expansion into hematologic malignancies beyond solid tumors. Financial management has been a critical focus, with the company reducing its annual cash burn from approximately $54 million in 2023 to $41 million in 2024, indicating improved operational efficiency. However, the declining cash position from $27.7 million to $21.8 million between Q4 2024 and Q1 2025 highlights the ongoing funding challenges typical of clinical-stage biotechnology companies.
NXTC company profile · for informational purposes only — not investment advice.
Track NXTC with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free